[Epidermolysis bullosa acquisita ausgelöst durch Atezolizumab]

J Dtsch Dermatol Ges. 2023 Nov;21(11):1407-1409. doi: 10.1111/ddg.15203_g.

[Article in German]

¹ Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
² Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
³ Anatomical Pathology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

^# Contributed equally.

No abstract available

Keywords: Atezolizumab; Epidermolysis bullosa acquisita; Immuntherapie; anti-PD-L1; bullöse Dermatose; immunassoziierte unerwünschte Ereignisse.

Publication types